Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, ...

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...

Candel Therapeutics (CADL) announced it will deliver three presentations at the Society for Immunotherapy of Cancer, SITC, 40th Anniversary Annual ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on ...

Candel Therapeutics shares fell 8.27% after phase 2a trial data showed CAN-2409 improved NSCLC survival, but investors are concerned. The trial reported a median survival of 24.5 months, compared to 9 ...

In December, the share price of Candel Therapeutics surged by more than 200% when the company revealed the success of a phase 3 trial of its multimodal biological immunotherapy CAN-2409 (aglatimagene ...

A clinical-stage biopharmaceutical company looks forward to the year ahead with several promising developments in motion. Focused on the development of multimodal biological immunotherapies to help ...

Candel Therapeutics, Inc. has announced an underwritten public offering to raise $80 million through the sale of its common stock and pre-funded warrants. The company plans to use the proceeds to ...

Seeing as smartphones are now commonplace at events, concerts, and festivals, we may as well make them stand out as much as possible. That seems to be the idea behind Candel, a music-activated ...

Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., ...

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday potentially driven by continued momentum following the company’s announcement of positive phase 3 trial results for its ...